Business
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing
About this update from Spruce Biosciences, Inc.
[{"type":"text","content":" SAN FRANCISCO--(BUSINESS WIRE)--\nSpruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company’s global regulatory affairs and quality strategy.\n\n“Dr. Mansell brings extensive regulatory affairs and quality expertise at precisely the right time for Spruce, as we progress tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary syndrome,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “With more than 30 years of life sciences industry experience and a successful track record of managing complex drug development programs for numerous biopharmaceutical companies, Dr. Mansell is a strong addition to our executive team. We look forward to her leadership and guidance as we continue to advance our pipeline of novel treatments for patients with rare endocrine disorders.”\n\nDr. Mansell is a seasoned regulatory affairs, development strategy and program management professional, with over 30 years of industry experience in serious and rare diseases. She joins Spruce from Asklepios BioPharmaceutical (AskBio), where she served as Senior Vice President of Regulatory Affairs. Prior to AskBio, Dr. Mansell was Managing Director and Founder of White Oak BioPharma Solutions, a global regulatory strategy and operations consulting firm she established in 2006 to serve executive teams at a full range of companies, from startups to large companies. Prior to consulting, she held positions of increasing responsibility in regulatory affairs, pharmacovigilance, quality affairs and chemistry, manufacturing and controls with several biotechnology and pharmaceutical companies, including Curis, Sigma-Tau Research, Genzyme, CombinatoRx, Millennium Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals. Dr. Mansell earned a Ph.D. in pharmacokinetics and biopharmaceutics with a graduate minor in applied statistics from Oregon State University and an M.B.A. in finance and international business from New York University.\n\n\"Wi...